If it wasn't obvious before, Latigo Biotherapeutics is all in on its non-opioid pain treatment pipeline and that is highlighted further by the company's $150 million Series B capital raise. Announced ...
While the recent market dip has created bargains, some stocks have sufficiently lagged the market in the past year to warrant ...
CervoMed's stock soars 400% on promising dementia drug data. See more on insights, potential concerns, and what it means for ...
There’s been no shortage of either in recent weeks. Plunging valuations across the biotech sector were thrust into the ...
Learn more about whether Elastic N.V. or Vertex, Inc. is a better investment based on AAII's A+ Investor grades, which ...
Learn more about whether Open Text Corporation or Vertex, Inc. is a better investment based on AAII's A+ Investor grades, ...
Analysts may not have crystal balls, but they’re pretty bullish on Vertex’s 2028 outlook, despite its rocky stock performance ...
A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...
The luncheon featured a panel including Boston City Council President Ruthzee Louijeune and Nazia Jamal, an Afghan refugee.
Morgan Stanley raised the firm’s price target on Vertex (VERX) to $60 from $57 and keeps an Overweight rating on the shares. The company’s ...
At the Johnson Space Center Tuesday, NASA and Firefly Aerospace held a news conference to discuss the successful Blue Ghost ...
At the Johnson Space Center Tuesday, NASA and Firefly Aerospace held a news conference to discuss the successful Blue Ghost ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback